Figure 2

Quantitative proteomic analysis of low and moderately-high parasitemic vivax malaria patients. (A) Power calculation for determination of minimum number of required biological variants for 2D-DIGE analysis. Power curve exhibiting the minimum % effect size (fold-change) measurable as a function of sample size with 80% power at p < 0.05 level of statistical significance. (B) Dot plots representing the parasitemia range for both low and moderately-high parasitemic cohorts of vivax malaria patients (LPVM and MPVM) in terms of parasite counts/µL. (C) Representative 2D-DIGE image to compare serum proteome of HC and LP/MPVM patients. Graphical and 3D fluorescence intensity representations of a few selected statistically significant (p < 0.05; paired t-test) differentially abundant proteins such as HP, Apo A1, CP, Alpha-1B glycoprotein, Apo E and SAA in LPVM patients. (D) Trend of differential abundance for some serum proteins in LPVM and MPVM patients compared to HC identified in 2D-DIGE analysis. Data are represented as standardized log abundance of spot intensity measured in the biological variation analysis (BVA). Serum levels of HP and Apo A1 were found to be consistently lower in vivax malaria patients, while increased abundance for Apo E and SAA was observed in LPVM and MPVM patients compared to HC. (E) Graphical representation of the (normalized) protein abundance ratios between the samples (LPVM vs. HC and MPVM vs. HC), plotted against the total iTRAQ reporter ion intensities for a particular protein. A few selected differentially abundant proteins are labeled. (F) Representative MS/MS spectrum for two selected differentially abundant serum proteins identified in different parasitemic vivax malaria patients. Inset presenting the iTRAQ reporter ion intensities for representative peptides in healthy community controls (HC), and LPVM and MPVM patients.